Passage Bio Inc. Unveils Presentation on Advancements in Gene Therapy for Neurodegenerative Diseases

Reuters

2025/08/12

<a href="https://laohu8.com/S/PASG">Passage Bio</a> Inc. Unveils Presentation on Advancements in Gene Therapy for Neurodegenerative Diseases

Passage Bio Inc., a biotechnology company, has presented its latest corporate update, focusing on advancements in the treatment of neurodegenerative diseases. The presentation highlights the development of PBFT02, a gene therapy aimed at raising progranulin levels for conditions such as Frontotemporal Dementia (FTD) caused by GRN mutations. The company has established a suspension-based manufacturing process to support the late-stage development of this therapy. Passage Bio expects its cash reserves to sustain operations until the end of the first quarter of 2027. The upcoming milestones include reporting updated interim safety and biomarker data from Dose 2 in the second half of 2025 and seeking regulatory feedback on their manufacturing process and trial design in the first half of 2026. The presentation underscores the significant market opportunity for PBFT02 across various neurodegenerative disorders, including ALS and Alzheimer's Disease. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2558641396"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558641396\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558641396?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-12 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558641396","market":"nz","top_or_hot":-1,"title":"Passage Bio Inc. Unveils Presentation on Advancements in Gene Therapy for Neurodegenerative Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PASG\">Passage Bio</a> Inc. Unveils Presentation on Advancements in Gene Therapy for Neurodegenerative Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Passage Bio Inc., a biotechnology company, has presented its latest corporate update, focusing on advancements in the treatment of neurodegenerative diseases. The presentation highlights the development of PBFT02, a gene therapy aimed at raising progranulin levels for conditions such as Frontotemporal Dementia (FTD) caused by GRN mutations. The company has established a suspension-based manufacturing process to support the late-stage development of this therapy. Passage Bio expects its cash reserves to sustain operations until the end of the first quarter of 2027. The upcoming milestones include reporting updated interim safety and biomarker data from Dose 2 in the second half of 2025 and seeking regulatory feedback on their manufacturing process and trial design in the first half of 2026. The presentation underscores the significant market opportunity for PBFT02 across various neurodegenerative disorders, including ALS and Alzheimer's Disease. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Passage Bio Inc. Unveils Presentation on Advancements in Gene Therapy for Neurodegenerative Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPassage Bio Inc. Unveils Presentation on Advancements in Gene Therapy for Neurodegenerative Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-12 19:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PASG\">Passage Bio</a> Inc. Unveils Presentation on Advancements in Gene Therapy for Neurodegenerative Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Passage Bio Inc., a biotechnology company, has presented its latest corporate update, focusing on advancements in the treatment of neurodegenerative diseases. The presentation highlights the development of PBFT02, a gene therapy aimed at raising progranulin levels for conditions such as Frontotemporal Dementia (FTD) caused by GRN mutations. The company has established a suspension-based manufacturing process to support the late-stage development of this therapy. Passage Bio expects its cash reserves to sustain operations until the end of the first quarter of 2027. The upcoming milestones include reporting updated interim safety and biomarker data from Dose 2 in the second half of 2025 and seeking regulatory feedback on their manufacturing process and trial design in the first half of 2026. The presentation underscores the significant market opportunity for PBFT02 across various neurodegenerative disorders, including ALS and Alzheimer's Disease. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL1fFwd4:1","article_id":"2558641396","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558641396","pubTimestamp":1754997834,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Passage Bio Inc., a biotechnology company, has presented its latest corporate update, focusing on advancements in the treatment of neurodegenerative diseases. The presentation highlights the development of PBFT02, a gene therapy aimed at raising progranulin levels for conditions such as Frontotemporal Dementia  caused by GRN mutations. The company has established a suspension-based manufacturing process to support the late-stage development of this therapy. Passage Bio expects its cash reserves to sustain operations until the end of the first quarter of 2027. The upcoming milestones include reporting updated interim safety and biomarker data from Dose 2 in the second half of 2025 and seeking regulatory feedback on their manufacturing process and trial design in the first half of 2026. The presentation underscores the significant market opportunity for PBFT02 across various neurodegenerative disorders, including ALS and Alzheimer's Disease. You can access the full presentation through t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PASG":"Passage Bio, Inc."},"translate_title":"Passage Bio Inc.推出神经退行性疾病基因治疗进展演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PASG":0.9},"content_text":"Passage Bio Inc. Unveils Presentation on Advancements in Gene Therapy for Neurodegenerative Diseases\n    \n\n        Passage Bio Inc., a biotechnology company, has presented its latest corporate update, focusing on advancements in the treatment of neurodegenerative diseases. The presentation highlights the development of PBFT02, a gene therapy aimed at raising progranulin levels for conditions such as Frontotemporal Dementia (FTD) caused by GRN mutations. The company has established a suspension-based manufacturing process to support the late-stage development of this therapy. Passage Bio expects its cash reserves to sustain operations until the end of the first quarter of 2027. The upcoming milestones include reporting updated interim safety and biomarker data from Dose 2 in the second half of 2025 and seeking regulatory feedback on their manufacturing process and trial design in the first half of 2026. The presentation underscores the significant market opportunity for PBFT02 across various neurodegenerative disorders, including ALS and Alzheimer's Disease. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}